Janssen Pharmaceuticals, Inc., manufacturers a wide variety of products to meet the needs of healthcare professionals and patients. Products marketed and manufactured by Janssen include those to control and combat attention deficit hyperactivity disorder (ADHD), acid reflux disease, infectious diseases, bipolar I disorder, schizophrenia, Alzheimer’s disease, epilepsy, migraine prevention and treatment, and pain management.
Jansen Pharmaceuticals is a pharmaceutical branch of Johnson & Johnson. Johnson & Johnson is headquartered in New Brunswick, New Jersey, with 250 subsidiary companies with operations in over 57 countries and products sold in over 175 countries. Johnson & Johnson’s worldwide sales were more than $65 billion in 2014, and their most famous products include Band-Aids, Tylenol, Neutrogena skin care products, and Acuvue contact lenses.
Initially, however, Janssen Pharmaceuticals was lead by Dr. Janssen who worked to create mental health medications. Janssen Pharmaceutica became part of Johnson & Johnson in 1961, but according to the company, Janssen Pharmaceuticals “remains guided by Dr. Janssen’s values of excellence and innovation” as they create new medications and services to address the needs of oncology, immunology, neuroscience, infectious diseases, vaccines, and cardiovascular and metabolic diseases.
Today, Janssen Pharmaceuticals continues to produce a wide variety of medications and provides other products and services to meet the needs of healthcare professionals. Located in Titusville, New Jersey, the company was named after a leading Belgian pharmacologist and general practitioner, Dr. Paul Janssen.
In 2011, Janssen Pharmaceuticals was combined (within Johnson & Johnson) with other companies to form the Ortho-McNeil-Janssen Pharmaceutical operating units (McNeil Pediatrics, Ortho-McNeil, Ortho Women’s Health & Urology, Ortho-McNeil Neurologics, PriCara, and Janssen).
Paul Janssen worked for his father, Constant Janssen, who was a pharmaceutical distributor in Belgium in the early 1930s. In 1953, Paul Janssen started his own research laboratory within his father’s company and by 1955 he had developed his first drug called Neomeritine, which was used to relieve menstrual pain. Later Paul Janssen formed his own legal entity, N.V. Research Laboratorium C. Janssen, and separated from his father. In 1961, the American corporation Johnson & Johnson purchased his company, and the company’s name was changed to Janssen Pharmaceutica. The company continued to be led by Paul Janssen. In the next thirty years the company continued to grow and expand into a multinational company. By 2001, however, much of the research and development activities had been moved to the United States and reorganization of research activities were transferred to the Johnson & Johnson Pharmaceutical Research Development (JJPRD) organization. Johnson & Johnson credits much of the success of the pharmaceutical company to the vision of the original founder Paul Janssen. The company continues to be led by other talented and motivated employees who are focused on producing scientifically and commercially successful products.
Xarelto had been approved by the U.S. FDA for the prevention and treatment of blood clotting. Approval was given after extensive clinical trials evaluating rivaroxaban. In fact, rivaroxaban is one of the most studied oral, Factor Xa inhibitors in the world today. Rivaroxaban, which is marketed by Janssen under the name Xarelto, is being developed jointly by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare.
Janssen Pharmaceuticals and its parent company Johnson & Johnson were found by several juries across the United States to have “deceptively promoted” the antipsychotic drug Risperdal. Beginning in October 2012, Janssen Pharmaceuticals began settling lawsuits that were part of a consolidated litigation pending in Pennsylvania State Court in Philadelphia. In fact, the company has been forced to pay millions of dollars in damages to plaintiffs in Texas, South Carolina, Louisiana, and Arkansas. Claimants claimed the company put “profits before people.” Courts agreed by charging that the sales practices of the company were unethical. One charge alleged that bribes were paid to Omnicare, the largest company supplying pharmaceutical drugs to nursing homes, encouraging sales representatives to promote Risperdal as “effective and safe for elderly patients” and to encourage home physicians to push the product on patients for unapproved uses.